Adding Pfizer and Astellas Pharma’s Xtandi to hormone therapy significantly cut the risk of prostate cancer spreading compared to hormone therapy alone, trial findings show.
6th February 2018
VCCP Health has cleaned up at year's PM Society Awards, taking home a record 10 Gold gongs, as well as three Silver and three Bronze awards, for its work across pharmaceutical and healthcare advertising and communications.
5th February 2018
Manchester, UK-based LIG Biowise has raised £1.8 million in Series A fundraising, to further develop its ultra-rapid diagnostic device.
5th February 2018
A small study involving GPs based in the South West has revealed the key factors driving a large number of doctors out of the profession, prompting GPs leaders to warn that the workforce is in a “precarious state”.
5th February 2018
Breast cancer mortality rates have dropped 10 percent in five years, according to the latest analysis of data by Cancer Research UK.
5th February 2018
Health experts are calling for a ring-fenced tax to help plug the huge gaps in NHS and social care budgets.
5th February 2018
This highly prestigious competition for clinical researchers in the Americas is now closed for entry. PharmaTimes Media has reported a surge in entrants to this year’s Clinical Researcher of the Year competition, with over 45% more applicants passing the MCQ than in 2017.
2nd February 2018
PharmaTimes Media has reported a substantial increase in the number of MCQ passes and essay submissions for this year’s International Clinical Researcher of the Year competition.
2nd February 2018
Eisai and Bial’s epilepsy drug Zebinix has shown effectiveness on par with that of the current standard of care in newly diagnosed focal epilepsy patients.
2nd February 2018
The number of men dying from prostate cancer has overtaken the number of women dying from breast cancer for the first time, with the disease now the UK’s third biggest cancer killer.
2nd February 2018
Anglo-Swedish drugs giant AstraZeneca has booked a 3 percent rise in fourth-quarter sales to $5.8 billion, after growth in product sales was recorded following a number of years of decline.
2nd February 2018
The National Institute for Health and Care has issued final guidelines rejecting AstraZeneca’s Faslodex for certain patients with breast cancer.
2nd February 2018
Sanofi has asked European regulators to review an experimental medicine being developed in partnership with the Drugs for Neglected Disease initiative (DNDi) for sleeping sickness, which is endemic in Africa.
1st February 2018
The National Institute for Health and Care Excellence has issued a final green light securing routine NHS funding for Roche’s Perjeta in patients with a certain type of breast cancer.
1st February 2018
Janssen’s Imbruvica will be routinely available on the NHS to treat certain patients with mantle cell lymphoma (MCL), after cost regulators issued a final green light for the drug.
1st February 2018
